C-reactive protein: History and revival

European Journal of Internal Medicine

Volumn 13, Issue 7, 2002, Pages 412-422

  Ablij, Hans C ^a   Meinders, Arend E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; C reactive protein; Clinical use; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROBUCOL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DISEASE MARKER; HOST RESISTANCE; HUMAN; INFLAMMATION; MYCOSIS; OPSONIZATION; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT;

EID: 0036792245     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(02)00132-2     Document Type: Review

References (68)

1. Tillet W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the Pneumococcus. J Exp Med. 52:1930;561-571.
2. Gotschlich E.C. C-Reactive protein. A historical overview. Ann NY Acad Sci 389:1982;1.
3. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med. 340:(6):1999;448-454.
4. Kushner I, Volanakis JE, Gewurz H, editors. C-reactive protein and the plasma protein response to tissue injury. Ann NY Acad Sci 1982;389.
5. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38:2001;189-197.
6. Thompson D., Pepys M.B., Wood S.P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 7:(2):1999;169-177.
7. Du Clos T.W., Zlock T.L., Rubin R.L. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol. 141:1988;4266-4270.
8. Du Clos T.W. C-Reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol. 143:(8):1989;2553-2559.
9. Potempa L.A., Siegel J.N., Gewurz H. Binding reactivity of C-reactive protein for polycations. II Modulatory effects of calcium and phosphocholine. J Immunol. 127:(4):1981;1509-1514.
10. DiCamelli R., Potempa L.A., Siegel J., et al. Binding reactivity of C-reactive protein for polycations. J Immunol. 125:1980;1933-1938.
11. Taylor W.A., Ku N.O., Mortensen R.F. Both human IL-1 and IL-6 induce synthesis of C-reactive protein (CRP) by the PLC/PRF/5 hepatoma cell line. II Modulatory effects of calcium and phosphocholine. J. Immunol. 127:(4):1981;1509-1514.
12. Toniatti C., Arcone R., Majello B., et al. Regulation of the C-reactive protein gene, a major marker of inflammation and cancer. Mol Biol Med. 7:1990;199-212.
13. Ganter U., Arcone R., Toniatti C., et al. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 8:1989;3773-3779.
14. Hutchinson W.L., Noble E.G., Hawkins P.N., Pepys M.B. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Ivest. 94:1994;1390-1396.
15. Vigushin D.M., Pepys M.B., Hawkins P.N. Metabolic and scintigraphic studies of radioionated human C-reactive protein in health and disease. J Clin Invest. 90:1993;1351-1357.
16. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer disease. Brain Res. 887:2000;80-89.
17. Yasojima K., Schwab C., McGeer E.G., et al. Generation of C-reactive protein an complement components in atherosclerotic plaques. Am J Pathol. 158:(3):2001;1039-1051.
18. Kuta A.E., Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med. 164:1986;321-326.
19. Gould J.M., Weiser J.N. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 69:(3):2001;1747-1754.
20. Gewurz H., Zhang X.H., Lint T.F. Structure and function of the pentraxins. Curr Opin Immunol 7:1995;54-64.
21. Agrawal A., Shrive A.K., Greenhough T.J., Volanakis J.E. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 166:2001;3998-4004.
22. Wolbink G.J., Brouwer M.C., Buysmann S., Ten Berge I.J.M., Hack C.E. CRP-mediated activation of complement in vivo. Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 157:1996;473-479.
23. Gershov D., Kim S.J., Brot N., et al. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustain an anti-inflammatory innate immune response: implications for systemic auto-immunity. J Exp Med. 192:2000;1353-1363.
24. Zouki C., Haas B., Chan J.S.D., et al. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol. 167:2001;5355-5361.
25. Zouki C., Beauchamp M., Baron C., et al. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest. 100:1997;522.
26. Salonen E.M., Vaheri A. C-reactive protein in acute viral infections. J Med Virol. 8:(3):1981;161-167.
27. Heiskanen-Kosma T., Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral etiology of community-acquired pneumonia in children in primary healthcare settings. Scand J Infect Dis. 32:(4):2000;399-402.
28. Jaye D.L., Waites K.B. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J. 16:(8):1997;735-746.
29. Otterness I.G. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 24:(2):1994;91-104.
30. Moutsopoulos H.M., Elkon K.B., Mavridid A.K., et al. Serum C-reactive protein in primary Sjogren's syndrome. Clin Exp Rheumatol. 1:(1):1983;57-58.
31. ter Borg E.J., Horst G., Limburg P.C., et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 17:(12):1990;1642-1648.
32. Meijer C., Huysen V., Smeenk P., et al. Profiles of cytokines (TNF alpha and IL-6) and the acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 2:1993;359-365.
33. Gabay C., Roux-Lombard P., de Moerlose P., et al. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol. 20:1993;815-821.
34. Mazlam M.Z., Hodgson H.J.F. Interrelations between interleukin-6, interleukin-1β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut. 35:1994;77-83.
35. Olson R.E. Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr. 47:2000;55-78.
36. Napoli C., D'armiento F.P., Mancini F.P., et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into atherosclerotic lesions. J Clin Invest. 100:1997;2680.
37. Ross R. Atherosclerosis. An inflammatory disease. New Engl J Med. 340:1999;115-126.
38. Cheng G., Loree H.M., Kamm R.D., et al. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation. 87:1993;1179-1187.
39. Kiefer P., Giummelly P., Schjoth B., et al. Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis. 157:(1):2001;251-254.
40. Lee R.T., Schoen F.J., Loree H.M., et al. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol. 16:(8):1996;1070-1073.
41. Bhakdi S., Torzewski M., Klouche M., Hemmes M. Complement and atherogenesis. Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 19:1999;2349-2354.
42. Ridker P.M., Hennekes C.H., Buring J.E., et al. C-reactive protein and other inflammatory markers in the prediction of cardiovascular disease in women. New Engl J Med. 342:(12):2000;836-843.
43. Erren M., Reinecke H., Junker R., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol. 19:1999;2355-2363.
44. Diehl E.E., Haines G.K., Radosevich J.A., et al. Immunohistochemical localization of modified CRP in normal vascular tissue. Am J Med Sci. 319:2000;77.
45. Yudkin J.S., Stehhouwer C.D.A., Emeis J.J., et al. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 19:1999;972-978.
46. Ballou S.P., Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 4:1992;361-368.
47. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
48. Pasceri V., Chang J., Willerson J.T., et al. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation. 103:2001;2531-2534.
49. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. New Engl J Med. 331:1994;417-424.
50. Koenig W., Sund M., Frohlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 99:1999;237-242.
51. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New Engl J Med. 344:(26):2001;1959-1965.
52. Ridker P.M. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818.
53. Di Napoli M., Papa F., Bocola V. C-Reactive protein in ischemic stroke. An independent prognostic factor. Stroke. 32:2001;917-924.
54. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham Study. Stroke. 32:2001;2575-2579.
55. Rifai N., Ridker P.M. High-sensitive C-reactive protein: a novel promising marker of coronary heart disease. Clin Chem. 47:2001;403-411.
56. Lyn P., Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev. 6:(3):2000;248-271.
57. Albert M.A., Danielson E., Rifai N., et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. J Am Med Assoc. 286:2001;640-670.
58. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
59. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med. 336:1997;973-979.
60. Kennon S., Price C.P., Mills G.P., et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol. 37:2001;1266-1270.
61. Maass M., Bartels C., Kruger S., et al. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis. 140:1998;S25-30.
62. Shor A., Kuo C., Patton D.L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 82:1992;158-161.
63. Kou C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000;Suppl 3:S432-6.
64. Johnston C.S., Messina L.M., Browner W.S., et al. C-reactive protein and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke. 32:2001;2748-2752.
65. Mashima R., Witting P.K., Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol. 12:2001;411-418.
66. Yusuf S., Dagenais G., Pogue J. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). New Engl J Med. 342:2000;154-160.
67. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 13:(357(9250)):2001;101-105.
68. Langlois M, Duprez D, Delanghe J et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001:1863-8.